These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 1423284)
1. Binding of human single-stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum (II). Clugston CK; McLaughlin K; Kenny MK; Brown R Cancer Res; 1992 Nov; 52(22):6375-9. PubMed ID: 1423284 [TBL] [Abstract][Full Text] [Related]
2. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504 [TBL] [Abstract][Full Text] [Related]
3. Human replication protein A preferentially binds cisplatin-damaged duplex DNA in vitro. Patrick SM; Turchi JJ Biochemistry; 1998 Jun; 37(24):8808-15. PubMed ID: 9628743 [TBL] [Abstract][Full Text] [Related]
4. Recognition of platinum-induced DNA damage by nuclear proteins: screening for mechanisms. Marples B; Adomat H; Billings PC; Farrell NP; Koch CJ; Skov KA Anticancer Drug Des; 1994 Oct; 9(5):389-99. PubMed ID: 7945723 [TBL] [Abstract][Full Text] [Related]
5. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660 [TBL] [Abstract][Full Text] [Related]
6. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057 [TBL] [Abstract][Full Text] [Related]
7. Stable binding of human XPC complex to irradiated DNA confers strong discrimination for damaged sites. Batty D; Rapic'-Otrin V; Levine AS; Wood RD J Mol Biol; 2000 Jul; 300(2):275-90. PubMed ID: 10873465 [TBL] [Abstract][Full Text] [Related]
8. Cisplatin-DNA damage recognition proteins in human tumour extracts. Bissett D; McLaughlin K; Kelland LR; Brown R Br J Cancer; 1993 Apr; 67(4):742-8. PubMed ID: 8471431 [TBL] [Abstract][Full Text] [Related]
9. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Plooy AC; van Dijk M; Lohman PH Cancer Res; 1984 May; 44(5):2043-51. PubMed ID: 6538808 [TBL] [Abstract][Full Text] [Related]
10. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875 [TBL] [Abstract][Full Text] [Related]
11. [Molecular and cellular aspects of cis-diamminedichloroplatinum (II) interactions with DNA]. Zastawny TH; Oliński R Postepy Hig Med Dosw; 1993; 47(2):103-23. PubMed ID: 8415320 [TBL] [Abstract][Full Text] [Related]
12. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells. Fram RJ; Woda BA; Wilson JM; Robichaud N Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559 [TBL] [Abstract][Full Text] [Related]
13. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells. Frühauf S; Zeller WJ Cancer Res; 1991 Jun; 51(11):2943-8. PubMed ID: 2032232 [TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel protein that specifically binds to DNA modified by N-acetoxy-acetylaminofluorene and cis-diamminedichloroplatinum. Pietrowska M; Widłak P Acta Biochim Pol; 2005; 52(4):867-74. PubMed ID: 15940347 [TBL] [Abstract][Full Text] [Related]
15. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody. Tilby MJ; Johnson C; Knox RJ; Cordell J; Roberts JJ; Dean CJ Cancer Res; 1991 Jan; 51(1):123-9. PubMed ID: 1703029 [TBL] [Abstract][Full Text] [Related]
16. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro. Shellard SA; Hosking LK; Hill BT Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800 [TBL] [Abstract][Full Text] [Related]
17. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Yang LY; Li L; Keating MJ; Plunkett W Mol Pharmacol; 1995 May; 47(5):1072-9. PubMed ID: 7746274 [TBL] [Abstract][Full Text] [Related]
18. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV). Yoshida M; Khokhar AR; Siddik ZH Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266 [TBL] [Abstract][Full Text] [Related]
19. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. Zhai X; Beckmann H; Jantzen HM; Essigmann JM Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223 [TBL] [Abstract][Full Text] [Related]
20. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt W; Chaney SG Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]